Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors
Almost No Patients Required Post-Treatment Factor Replacement Therapy
Executive Summary
UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.
You may also be interested in...
Finance Watch: Biopharma IPO Market Silence Continues In The US
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
Signs Of Long-Term Efficacy Boost UniQure’s Hem B Gene Therapy
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
Gene Therapy Firm Freeline Successfully Tops Up Series C
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.